10:10am ET
Investing
Here’s What Insiders Are Buying to Wrap Up the Year
As the year wound to a close, the most notable insider buying was focused on biotech stocks, but an oil and gas company CEO also returned to the buy window.
Companies
/Healthcare
Verrica Pharmaceuticals Inc
$4.72
▲ $0.23 (+5.12%) today
Markets closed · 9:09am ET
Today · % change
Fundamentals
Market Cap
$81.1M
Profit Margin
-102.8%
Revenue (TTM)
$30.3M
EPS (TTM)
$-1.74
52-Week Range
$3 – $10
Street Target
$13.83
About Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc is a pioneering dermatology-focused biopharmaceutical company. It specializes in developing innovative treatments for skin diseases, including common and genital warts, basal cell carcinoma, and plantar warts. Its leading product, YCANTH (VP-102), is making strides in phase III trials for common warts and has shown promise in other skin conditions. The company also explores cancer treatments with VP-315 and targets plantar warts with VP-103. Founded in 2013 and based in West Chester, Pennsylvania, Verrica Pharmaceuticals is committed to advancing dermatological care worldwide.
VRCA Coverage
9:03am ET
Investing
Buffett, Dollar Tree Purchases Highlight Pre-Christmas Insider Buying
Warren Buffett's Berkshire Hathaway has again bolstered its stake in Occidental Petroleum, and action at Dollar Tree also highlights recent insider buying.